Literature DB >> 20106837

A cost-effectiveness analysis of in-vitro fertilization by maternal age and number of treatment attempts.

Alison Griffiths1, Suzanne M Dyer, Sarah J Lord, Chris Pardy, Ian S Fraser, Simon Eckermann.   

Abstract

BACKGROUND: The increase in use and costs of assisted reproductive therapies including in-vitro fertilization (IVF) has led to debate over public funding. A decision analytic model was designed to estimate the incremental cost-effectiveness of IVF by additional treatment programmes and maternal age.
METHODS: Data from the Australian and New Zealand Assisted Reproductive Database were used to estimate incremental effects (live birth and other pregnancy outcomes) and costs for cohorts of women attempting up to three treatment programmes. A treatment programme included one fresh cycle and a variable number of frozen cycles dependent on maternal age.
RESULTS: The incremental cost per live birth ranged from AU dollars 27 373 and AU dollars 31 986 for women aged 30-33 on their first and third programmes to AU dollars 130 951 and AU dollars 187 515 for 42-45-year-old women on their first and second attempts. Overall, these trends were not affected by inclusions of costs associated with ovarian hyperstimulation syndrome or multiple births.
CONCLUSIONS: This study suggests that cost per live birth from IVF increases with maternal age and treatment programme number and indicates that maternal age has the much greater effect. This evidence may help decisionmakers target the use of IVF services conditional on societal willingness to pay for live births and equity considerations.

Entities:  

Mesh:

Year:  2010        PMID: 20106837     DOI: 10.1093/humrep/dep418

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  11 in total

1.  Assessing predictors for the success of GnRH antagonist protocol in reproductive women in IVF/ICSI - in fresh cycles.

Authors:  An-Cong Wang; Ying Wang; Feng-Xia Wu; Dong-Yi Zhu
Journal:  Biomed Rep       Date:  2017-09-14

2.  Should there be a female age limit on public funding for assisted reproductive technology?

Authors:  Drew Carter; Amber M Watt; Annette Braunack-Mayer; Adam G Elshaug; John R Moss; Janet E Hiller
Journal:  J Bioeth Inq       Date:  2013-01-04       Impact factor: 1.352

3.  Female ageing and reproductive outcome in assisted reproduction cycles.

Authors:  T Y Tan; S K Lau; S F Loh; H H Tan
Journal:  Singapore Med J       Date:  2014-06       Impact factor: 1.858

Review 4.  Evaluating Cost-effectiveness of Interventions That Affect Fertility and Childbearing: How Health Effects Are Measured Matters.

Authors:  Jeremy D Goldhaber-Fiebert; Margaret L Brandeau
Journal:  Med Decis Making       Date:  2015-04-29       Impact factor: 2.749

5.  Outcome of assisted reproductive technology in women aged 40 years and older.

Authors:  Abbas Aflatoonian; Maryam Eftekhar; Farnaz Mohammadian; Fariba Yousefnejad
Journal:  Iran J Reprod Med       Date:  2011

6.  The ASTUTE Health study protocol: deliberative stakeholder engagements to inform implementation approaches to healthcare disinvestment.

Authors:  Amber M Watt; Janet E Hiller; Annette J Braunack-Mayer; John R Moss; Heather Buchan; Janet Wale; Dagmara E Riitano; Katherine Hodgetts; Jackie M Street; Adam G Elshaug
Journal:  Implement Sci       Date:  2012-10-22       Impact factor: 7.327

7.  Estimating the long-term effects of in vitro fertilization in Greece: an analysis based on a lifetime-investment model.

Authors:  Vassilis Fragoulakis; Nikolaos Maniadakis
Journal:  Clinicoecon Outcomes Res       Date:  2013-06-20

8.  Comparison of lifestyle in fertile and infertile couples in Kermanshah during 2013.

Authors:  Tahereh Khosrorad; Mahrokh Dolatian; Hedyeh Riazi; Zohreh Mahmoodi; Hamid Alavimajd; Soodeh Shahsavari; Mitra Bakhtiari
Journal:  Iran J Reprod Med       Date:  2015-09

Review 9.  Role of GnRH Neurons and Their Neuronal Afferents as Key Integrators between Food Intake Regulatory Signals and the Control of Reproduction.

Authors:  Juan Roa
Journal:  Int J Endocrinol       Date:  2013-09-11       Impact factor: 3.257

10.  Economic evaluation of highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone in fresh and frozen in vitro fertilization/intracytoplasmic sperm-injection cycles in Sweden.

Authors:  Jaro Wex; Ahmed M Abou-Setta
Journal:  Clinicoecon Outcomes Res       Date:  2013-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.